Dr. Guang Han 韩光
Chief Physician
Department of Radiation Oncology, Hubei Cancer Hospital, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiotherapy, chemotherapy, targeted and immunotherapy for lung, esophageal, nasopharyngeal, head and neck squamous cell, and breast cancers. Techniques include stereotactic body radiotherapy, image-guided, adaptive, and four-dimensional radiotherapy.
Dr. Han is a Chief Physician with a doctorate in oncology and a master’s supervisor. Dr. Han was a visiting scholar at the Buffett Cancer Center, University of Nebraska Medical Center (UNMC), and has over 10 years of experience in basic and clinical cancer research.
Professional roles
- Member, Chinese Medical Association
- Chair, Nasopharyngeal Cancer Expert Committee, Hubei Clinical Oncology Society
- Vice Chair, Radiation Oncology Branch, Hubei Medical Doctor Association
- Vice Chair, Molecular Markers and Translational Medicine Committee, Hubei Anti-Cancer Association
Name order: in Chinese the family name comes first (Han Guang). Papers usually list the name as Guang Han or Han G.
Selected publications
75 papers on PubMed matched by name and affiliation; 29 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Immunol, 2026 (senior author): The CCL2-CCR2 axis in primary lung cancer and pulmonary metastasis: from molecular mechanisms to therapeutic potentials. PubMed 42787504
- iScience, 2026 (senior author): Tumor treating fields combined with concurrent chemoradiotherapy for glioblastoma: A multi-institutional analysis. PubMed 42389573
- Breast Cancer (Dove Med Press), 2026 (senior author): Efficacy and Safety of Neoadjuvant Stereotactic Body Radiotherapy (SBRT) Combined with Chemoimmunotherapy in Locally Advanced Breast Cancer: A Single-Center, Retrospective Pilot Study. PubMed 41822363
- Immunotargets Ther, 2025 (senior author): Durable Tumor Control with Multi-Organ Immune-Related Adverse Events Following Immune Checkpoint Inhibitor and Sequential Radiotherapy in Locally Advanced NSCLC: A Case Report. PubMed 41403878
- BMJ Open, 2025 (senior author): Neoadjuvant stereotactic body radiotherapy combined with chemotherapy and Ivonescimab for Chinese luminal-type breast cancer patients: study protocol for a single-arm, open-label, phase II trial. PubMed 40935417
- Future Oncol, 2025 (senior author): Research progress on treatment-associated pneumonitis in lung cancer patients undergoing radiotherapy and immunotherapy. PubMed 40625086
- Am J Cancer Res, 2025 (senior author): Predictive nomogram for risk of pulmonary infection in lung cancer patients undergoing radiochemotherapy: development and performance evaluation. PubMed 40084356
- Curr Comput Aided Drug Des, 2025 (senior author): Comprehensive Analysis and Experimental Validation of FOXD2 as a Novel Potential Prognostic Biomarker Associated with Immune Infiltration in Head and Neck Squamous Cell Carcinoma. PubMed 38629358
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion